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To the Editor:
The letter from Drs McKenzie and Szepietowski in connection
with our article (Hu et al, 2000) extended our observation and
discussed the probable function of LIF in skin. The letter is helpful
in understanding the cytokine network in skin. We agree with
most of their viewpoints.
In the letter, however, they wrote: Hu et al ``recorded no or
negligible LIF immunoreactivity in disease control skin'', whereas
their group ``always observed LIF immunoreactivity in normal
skin''. Quantitative comparison should be taken under the same
conditions. In McKenzie's report (Paglis et al, 1996), the LIF
immunostaining in normal skin seemed strong. But they used
different immunohistochemical conditions from ours, by which the
intensity of immunostain will be strongly affected. We used a
different antibody (an af®nity-puri®ed polyclonal antibody against
the LIF peptide, N-18, Santa Cruz, CA), a different immunor-
eactive condition (concentration of primary antibody 1 mg per ml,
incubated for 12 h), and a different section method (paraf®n-
embedded section). The normal skin samples they used were
obtained from surgery patients, and transported in DMEM medium
to the laboratory. Traumatic reaction might occur in this step,
resulting in the elevation of cytokine concentrations (including
LIF). On the contrary, we ®xed all the biopsy samples immediately
in formalin. Furthermore, the ethnic difference should also be
considered as an effective factor.
In our article, we compared LIF immunoreactivity in biopsied
skins between ALS and other neurodegenerative disease controls.
For ethical reasons, we did not include any biopsied skin specimens
from normal subjects. We could not know how strong the LIF
immunoreactivity was in normal skin, and whether immunor-
eactivity in ALS skin was just the same as that in normal skin.
Nevertheless, we did not negate the LIF immunoreactivity in the
skin of disease control. We also thought that a low level of LIF
immunoreactivity in normal skin was reasonable. We emphasized
that ALS patients expressed far more LIF in skin than the disease
control subjects did. In our study, the immunoreactivities in the
skins of ALS cases and controls were detected simultaneously under
the same experimental conditions. The immunoreactive intensity
was expressed as optical density (OD, arbitrary unit). The OD of
ALS skins ranged from 9.0 to 1.9, while that of disease controls
ranged from 1.8 to 0.4. Although the immunoreactive pattern in
ALS with an OD of 1.9 was similar to that in disease-control with
an OD of 1.8, the ALS group was signi®cantly different from the
disease control group statistically. Furthermore, we found that the
OD in ALS showed a progressive increase in relation to duration of
the illness (r = 0.82, p < 0.01), suggesting that OD in long duration
patients should be higher than that in normal controls. The OD in
ALS patients with a duration of 3.2 y was 9.0, while that of 0.4 y
was only 1.8. We do not believe OD in normal skin could be as
high as 9.0, unless they were proved by simultaneous and
quantitative comparison.
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Limited Concordance Between ``Oakmoss'' and Colophony in
Clinical Patch Testing
To the Editor
Recently, Lepoittevin et al (2000) reported on the detection of
various resin acids in ``treemoss'' perfume extracts, some of them
identical to those found in colophony and its oxidation products,
respectively. Furthermore, a considerable contamination of ``oak-
moss'' raw material, especially the material used by Trolab
(Reinbek, Germany) for manufacturing ``oakmoss'' patch test
material, with these resin acids was found (5.6% resin acids and
0.7% 7-oxo-dehydroabietic acid, a sensitizing oxidation product of
colophony). Accordingly, the majority of their 17 patients
sensitized to colophony not only reacted to ``treemoss'' (n = 12),
but also to ``oakmoss'' by Trolab (n = 9), but rarely to ``oakmoss''
by Chemotechnique (Malmo, Sweden, n = 2) containing less than
0.4% wt/wt resin acids.
To put these challenging results pointing to a tremendous
potential for misdiagnosis into the perspective of clinical patch
testing with ``oakmoss'', national surveillance data of the IVDK
(http://www.ivdk.gwdg.de) collected between January 1992 and
December 1999, in the 34 participating centers (see footnote 1)
were analyzed. Test substances were supplied by Trolab, results
based on readings at 72 h following the standards of the
International Contact Dermatitis Research Group. In the above
period, 67,306 patients were patch tested to colophony (20% in
petrolatum), which is contained in the standard test series, with
1433 (2.1%) weakly positive (``+''), 1154 (1.7%) strongly
positive (``++'' or ``+++'') and 697 (1.0%) equivocal (``?'')
or, rarely, irritant reactions. At the same time, 12,823 patients
were patch tested to ``oakmoss'' (1% in petrolatum, the same as
used by Lepoittevin et al, 2000), which is included in the
fragrances series and two other special series. These are tested in
a more focussed way, often as a breakdown of the fragrance
mix in case of a positive reaction. Nearly all patients (98.4%)
were also tested with colophony. Results obtained in this
subgroup (n = 12,614) are presented in the format of a 5 3 5
contingency table (Table I) showing the joint distribution of
patch test reactions to both test substances. Altogether 27.0% of
all persons allergic to colophony reacted positively (``+'' to
``+++'') to ``oakmoss'', whereas only 5.5% positive reactions to
``oakmoss'' were found in the rest. This ®nding points to a
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